Mobile website
Archive > Volume 29 Issue 10 > 2022,29(10):863-870. DOI:10.3872/j.issn.1007-385X.2022.10.001 Prev Next
Expert Forum
New directions, new concepts, new challenges: the past and present of intratumoral immunotherapy for solid tumors
- Article
- Figures
- Metrics
- Preview PDF
- Reference
- Related
- Cited by
- Materials
Abstract:
Cancer immunotherapy has developed at a rapid pace in recent years and has significantly improved the prognosis of many patients with solid tumors. However, not all the patients produce a durable response, and its efficacy is often limited by immunotherapy-related toxicity. Currently, intratumoral immunotherapy is receiving increased attention as a tool for local immunotherapy. In this paper, we first introduce the current research status of immunotherapy in solid tumor and analyze the significant advantages of intratumoral immunotherapy in reducing systemic drug exposure and its adverse effects, enhancing tumor immunogenicity, and overcoming tumor heterogeneity based on the current status of immunotherapy of solid tumors; then, we briefly summarize the currently available drugs for intratumoral immunotherapy and the progress on their application; and finally, we also summarize the challenges and countermeasures faced by intratumoral immunotherapy in terms of efficacy evaluation and implementation, in order to promote and popularize the concept of intratumoral immunotherapy for solid tumors.
Keywords:
Project Supported:
Clc Number:
